Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Protein provides hope for new medicines to lower cholesterol

09.06.2005


An international research team has discovered a new target molecule, Fbw7, for developing drugs with the potential to complement or replace statins in the treatment of cardiovascular diseases. The findings are being published in the new issue of the scientific journal Cell Metabolism.



Cholesterol is a fat-like substance that is needed for the formation of our cells and for the production of hormones. The amount needed can be provided by the body itself, but our eating habits often lead to too much cholesterol. The surplus is stored in the walls of our vessels, thereby increasing the risk of cardiovascular disorders, the most common cause of death in the Western world. What‚s more, individuals with cardiovascular diseases run a greater risk of being overweight and contracting diabetes.

The protein SREBP regulates the genes that control the amount of cholesterol and other fats in cells. SREBP‚s ability to regulate the new production, metabolism, and uptake of cholesterol from the blood is extremely important in the liver, where huge quantities of cholesterol are absorbed and rendered harmless. SREBP is therefore a suitable target molecule for the development of new drugs for cardiovascular diseases, overweight, and diabetes.


The most common medicinal treatment for heightened levels of cholesterol today is a group of drugs called statins. These drugs activate SREBP and thus enhance the capacity of the liver to render cholesterol harmless. However, in high doses, statins can have side effects, since they also block the new production of necessary cholesterol in other cells in the body.

The useful effect takes place primarily in the liver‚s uptake from the blood, explains Johan Ericsson from the Ludwig Institute, Uppsala University, who led the study in collaboration with Harvard Medical School.

His team discovered in their molecular studies of the protein SREBP that it had a binding point that ought to suit the protein Fbw7, which had been identified by the Harvard researchers. It turned out that Fbw7 inhibited the metabolism of fat by breaking down SREBP. Consequently, inactivating Fbw7 led to greater amounts of SREBP and increased uptake of cholesterol.

Now we need to look more closely at the mechanisms behind the interaction between these two molecules. Fbw7 also has other important functions in the cell, so the goal is to be able to knock out its effect on SREBP only, says Johan Ericsson.

Anneli Waara | alfa
Further information:
http://www.cellmetabolism.org/content/current

More articles from Life Sciences:

nachricht Scientists spin artificial silk from whey protein
24.01.2017 | Deutsches Elektronen-Synchrotron DESY

nachricht Choreographing the microRNA-target dance
24.01.2017 | UT Southwestern Medical Center

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Scientists spin artificial silk from whey protein

X-ray study throws light on key process for production

A Swedish-German team of researchers has cleared up a key process for the artificial production of silk. With the help of the intense X-rays from DESY's...

Im Focus: Quantum optical sensor for the first time tested in space – with a laser system from Berlin

For the first time ever, a cloud of ultra-cold atoms has been successfully created in space on board of a sounding rocket. The MAIUS mission demonstrates that quantum optical sensors can be operated even in harsh environments like space – a prerequi-site for finding answers to the most challenging questions of fundamental physics and an important innovation driver for everyday applications.

According to Albert Einstein's Equivalence Principle, all bodies are accelerated at the same rate by the Earth's gravity, regardless of their properties. This...

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Breaking the optical bandwidth record of stable pulsed lasers

24.01.2017 | Physics and Astronomy

Choreographing the microRNA-target dance

24.01.2017 | Life Sciences

Spanish scientists create a 3-D bioprinter to print human skin

24.01.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>